Loading organizations...
§ Private Profile · San Mateo, CA, USA
Soteria Biotherapeutics is a technology company.
Soteria Biotherapeutics has raised $42.0M across 1 funding round.
Key people at Soteria Biotherapeutics.
Soteria Biotherapeutics has raised $42.0M in total across 1 funding round.
Soteria Biotherapeutics engineers next-generation immunotherapies, focusing on conditionally active bispecific T-cell engaging antibodies designed to target solid tumors. The company's innovative T-LITE™ platform integrates a small molecule-controlled switch into bispecific antibody therapies, enabling precise, pulsatile activation. This approach aims to deliver therapies with enhanced efficacy and safety by allowing controlled dosing and reduced side effects.
The company was established in 2018 by Alexander Martinko and Zachary Hill. Their foundational insight stemmed from the potential to improve immunotherapy outcomes for cancer patients by developing treatments with better control and fewer adverse reactions. The core technology powering Soteria Biotherapeutics was licensed from UC San Francisco.
Soteria Biotherapeutics' primary focus is on providing advanced treatment options for cancer patients suffering from solid tumors. The company envisions a future where its platform can offer safer and more effective therapeutic interventions, broadening the applicability of T-cell engaging antibodies for challenging cancers.
Key people at Soteria Biotherapeutics.
Soteria Biotherapeutics has raised $42.0M across 1 funding round. Most recently, it raised $42.0M Series A in May 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2021 | $42M Series A | David Allison, Nisha Marathe | Aglaia BioMedical Ventures, Keno Gutierrez, BGV (biogeneration Ventures), Forbion, Westlake Village BioPartners, Alexandria Venture Investments, M Ventures, David Morris, MD | Announced |
Soteria Biotherapeutics has raised $42.0M in total across 1 funding round.
Soteria Biotherapeutics's investors include David Allison, Nisha Marathe, Aglaia BioMedical Ventures, Keno Gutierrez, BGV (BioGeneration Ventures), Forbion, Westlake Village BioPartners, Alexandria Venture Investments, David Morris, MD.
Soteria Biotherapeutics is an immuno-oncology company developing next-generation bispecific T-cell engagers for solid tumor cancers using its proprietary T-LITE platform, which enables switchable activation for safer, more controllable therapies with reduced side effects.[1][2] The platform targets healthcare providers and cancer patients by leveraging the immune system to combat tumors more effectively than traditional bispecifics, addressing limitations like cytokine release syndrome.[1][2] Founded in 2018 and based in the San Francisco Bay Area (with addresses in San Francisco and San Mateo, California), it raised $42 million in Series A funding in 2021 led by Roche Venture Fund and 5AM Ventures, signaling strong early momentum in biotech.[2][4]
Soteria Biotherapeutics emerged in 2018 from innovations in controllable immunotherapy, focusing on bispecific T-cell engagers that activate only in the presence of a small-molecule switch, minimizing off-tumor toxicity.[1][2][4] While specific founders are not detailed in available sources, the company's launch was marked by a $42 million Series A round led by Roche Venture Fund and 5AM Ventures, highlighting immediate validation from top biotech investors.[2][4] Early traction came from the T-LITE platform's promise for solid tumors, where standard T-cell engagers struggle due to safety issues, positioning Soteria as a pioneer in "switchable" therapies.[1][4]
(Note: A separate Taiwan-based entity, Soteria Biotech Co., Ltd., develops unrelated medical software for respiratory diseases like OSAS, but this profile focuses on the U.S. immuno-oncology firm matching the query's technology context.[3])
Soteria rides the bispecific T-cell engager wave in immuno-oncology, a market exploding due to successes like Blincyto but hampered by toxicity in solid tumors—where Soteria's controllable platform fills a critical gap.[1][2] Timing aligns with surging demand for precision cancer therapies amid advances in antibody engineering and oral small-molecule combos, fueled by Big Pharma interest (e.g., Roche's lead investment).[4] Market forces like rising solid tumor incidence and regulatory push for safer CAR-T alternatives favor Soteria, influencing the ecosystem by pioneering "titratable" immunotherapies that could expand T-cell engager use beyond hematology.[1][2]
Soteria's T-LITE platform positions it for IND filings and Phase 1 trials in solid tumors, potentially yielding first-in-class data by 2026-2027 if preclinical promise holds.[1][2][4] Trends like combo therapies with PD-1 inhibitors and AI-optimized switches will shape its path, amplifying influence as Roche's network accelerates partnerships or acquisition.[4] As controllable immunotherapies mature, Soteria could redefine solid tumor treatment standards, building on its $42M launch to drive broader adoption of switchable biologics—echoing its mission to harness immunity safely from day one.[2][4]
